Dr. Berens studies the interaction between the immune system and cancer, specifically looking at how certain proteins in tumors can affect tumor behavior and treatment responses. He investigates aggressive forms of breast cancer, such as triple-negative breast cancer, which are harder to treat. Additionally, he explores methods to develop new cancer treatments by combining tiny proteins, called nanobodies, with enzymes to create more effective therapies that can selectively target cancer cells while sparing healthy ones.
Key findings
Higher levels of sialoglycoproteins in breast tumors are linked to more aggressive tumor types, including triple-negative breast cancers, highlighting a potential target for improved immunotherapy treatments.
One combination of nanobodies and enzymes increased cancer cell killing ability by over fivefold, paving the way for more specialized and effective cancer therapies.
IL-2 was found to be crucial for activating immune cells (CTLs), while IFN-gamma is not required for this process, clarifying the mechanisms of immune response activation.
Frequently asked questions
Does Dr. Berens study breast cancer?
Yes, Dr. Berens specifically studies aggressive forms of breast cancer, including triple-negative breast cancer.
What treatments has Dr. Berens researched?
He has researched new cancer therapies that involve combining nanobodies with enzymes to create targeted treatments that can effectively kill cancer cells.
Is Dr. Berens's work relevant to cancer patients?
Yes, his research aims to develop better treatment options for cancer patients, particularly those with aggressive cancer types.
What role does the immune system play in Dr. Berens's research?
Dr. Berens studies how immune responses can be harnessed for cancer treatment, particularly focusing on proteins that influence tumor behavior and immune activation.
How might Dr. Berens's findings impact future cancer therapies?
His findings could lead to the development of more effective and tailored cancer treatments, improving outcomes for patients with aggressive tumors.
Publications in plain English
Immunosuppressive glycoproteins associate with breast tumor fibrosis and aggression.
2022
Matrix biology plus
Metcalf KJ, Hayward MK, Berens E, Ironside AJ, Stashko C +2 more
Plain English This study looked at certain proteins, called sialoglycoproteins, in breast tumors that are more fibrous and aggressive. Researchers found that higher levels of these proteins were linked to more aggressive tumor types, with triple-negative breast cancers showing significantly higher levels of both the sialoglycoproteins and specific immune cells that suppress the body’s immune response. This matters because it highlights a potential new target for treatments that could improve how well patients respond to immunotherapy, especially for those with more aggressive types of breast cancer.
Who this helps: Patients with aggressive breast cancer types.
Synthetic Tuning of Domain Stoichiometry in Nanobody-Enzyme Megamolecules.
2021
Bioconjugate chemistry
Metcalf KJ, Kimmel BR, Sykora DJ, Modica JA, Parker KA +5 more
Plain English This study looked at a new way to create highly specialized treatments for cancer by combining tiny proteins called nanobodies with enzymes. Researchers found that by adjusting the number of each component in these combined molecules, they could improve how effectively the treatment worked, with one combination leading to more than a fivefold increase in cancer cell killing ability. This is important because it could lead to more effective cancer therapies that can specifically target harmful cells while minimizing damage to healthy ones.
Who this helps: This benefits cancer patients who may receive better, more effective treatments.
Lack of an obligate role for IFN-gamma in the primary in vitro mixed lymphocyte response.
1988
Journal of immunology (Baltimore, Md. : 1950)
Bucy RP, Hanto DW, Berens E, Schreiber RD
Plain English This study looked at two substances, IL-2 and IFN-gamma, to see how they help activate immune cells called CTLs in mice. The researchers found that IL-2 is crucial for the activation and multiplication of CTLs, while IFN-gamma did not play a required role in this process. Specifically, even when IFN-gamma was present, it did not contribute to CTL activation, confirming the importance of IL-2 instead.
Who this helps: This helps doctors and researchers working on immune responses in patients.
Kevin James Metcalf Mary-Kate Hayward Alastair J Ironside Connor Stashko E Shelley Hwang Valerie M Weaver Kevin J Metcalf Blaise R Kimmel Daniel J Sykora Justin A Modica
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.